CG Oncology
CGON· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +44.8% in FY2025
Arthur Kuan is the CEO of CG Oncology and was paid $11.9M in FY2025 (Dec), up 7%.
Pay$100 in the stock at the end of FY24 → $145
Executives7
See all- 1Arthur KuanChief Executive OfficerFY2025
- 2Ambaw BelletePresident and Chief Operating OfficerFY2025
- 3Vijay KasturiChief Medical OfficerFY2025
- 4Joshua F. PattersonGeneral Counsel, Chief Compliance Officer, and SecretaryFY2025
- 5Corleen RochePrior Chief Financial OfficerFY2025
- 6Robert Lapetina (PriorInterim Principal Financial and Accounting Officer)FY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCG Oncology paid its 7 named executives $25.8M in total in FY2025 (Dec). CEO Arthur Kuan was paid $11.9M of that.
| Name | |||
|---|---|---|---|
| Arthur KuanChief Executive Officer | |||
| Ambaw BelletePresident and Chief Operating Officer | |||
| Vijay KasturiChief Medical Officer | Not disclosed | Not disclosed | |
| Joshua F. PattersonGeneral Counsel, Chief Compliance Officer, and Secretary | Not disclosed | Not disclosed | |
| Corleen RochePrior Chief Financial Officer | |||
| Robert Lapetina (PriorInterim Principal Financial and Accounting Officer) | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for CG Oncology. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- James J. MuléDirector · 7 yr on the boardIndependent—Paid as an executive
- Brian LiuDirector · 3 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Susan E. GrafDirector · 2 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings5
See all| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Feb 27, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 26, 2024 | FY2023 |
